Emergent BioSolutions (NYSE:EBS) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Emergent BioSolutions (NYSE:EBS - Free Report) in a research note issued to investors on Friday,Benzinga reports. The firm currently has a $15.00 price target on the biopharmaceutical company's stock. HC Wainwright also issued estimates for Emergent BioSolutions' Q1 2026 earnings at $0.87 EPS, Q2 2026 earnings at $1.04 EPS, Q3 2026 earnings at $1.11 EPS and Q4 2026 earnings at $0.81 EPS.

Separately, StockNews.com downgraded shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Wednesday, March 5th.

Emergent BioSolutions Stock Up 0.5 %

Shares of NYSE:EBS traded up $0.03 during trading on Friday, hitting $5.75. The company's stock had a trading volume of 272,318 shares, compared to its average volume of 1,148,291. The company has a market capitalization of $312.44 million, a PE ratio of -1.40 and a beta of 1.80. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions has a fifty-two week low of $1.82 and a fifty-two week high of $15.10. The business has a 50 day moving average price of $8.48 and a two-hundred day moving average price of $8.73.

Remove Ads

Emergent BioSolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.40. The company had revenue of $194.70 million for the quarter, compared to the consensus estimate of $254.67 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same quarter in the prior year, the business earned ($0.77) EPS. As a group, research analysts expect that Emergent BioSolutions will post -0.63 EPS for the current fiscal year.

Insider Transactions at Emergent BioSolutions

In other news, Director Neal Franklin Fowler sold 35,000 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total transaction of $204,050.00. Following the completion of the sale, the director now owns 101,100 shares in the company, valued at approximately $589,413. The trade was a 25.72 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.20% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of EBS. Covestor Ltd boosted its stake in Emergent BioSolutions by 5,458.5% in the fourth quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 2,893 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of Emergent BioSolutions in the 4th quarter valued at about $63,000. Stifel Financial Corp purchased a new position in Emergent BioSolutions during the 3rd quarter worth approximately $96,000. E Fund Management Co. Ltd. acquired a new position in Emergent BioSolutions during the fourth quarter worth approximately $98,000. Finally, FORA Capital LLC purchased a new stake in Emergent BioSolutions in the third quarter valued at approximately $103,000. 78.40% of the stock is owned by hedge funds and other institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.